This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), Vera Therapeutics (VERA) and Regeneron (REGN)

Tipranks - Tipranks - Wed Jun 3, 7:08AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IDEAYA Biosciences (IDYA), Vera Therapeutics (VERA) and Regeneron (REGN) with bullish sentiments.

Claim 55% Off TipRanks

IDEAYA Biosciences (IDYA)

In a report released today, Gregory Renza from Truist Financial reiterated a Buy rating on IDEAYA Biosciences. The company’s shares closed last Monday at $28.94.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 18.1% and a 48.9% success rate. Renza covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Perspective Therapeutics, and Abivax SA Sponsored ADR. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for IDEAYA Biosciences with a $53.91 average price target, an 83.5% upside from current levels. In a report released today, TipRanks – Google also upgraded the stock to Buy with a $32.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Vera Therapeutics (VERA)

TD Cowen analyst Ritu Baral maintained a Buy rating on Vera Therapeutics today. The company’s shares closed last Monday at $33.94.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 46.4% and a 53.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Praxis Precision Medicines, and Milestone Pharmaceuticals. ;'>

Vera Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $77.63, which is a 121.6% upside from current levels. In a report issued on May 22, J.P. Morgan also maintained a Buy rating on the stock with a $86.00 price target.

Regeneron (REGN)

In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Regeneron, with a price target of $855.00. The company’s shares closed last Monday at $600.66.

According to TipRanks.com, Amin is a 4-star analyst with an average return of 9.6% and a 46.5% success rate. Amin covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, OKYO Pharma Limited Sponsored ADR, and BridgeBio Oncology Therapeutics. ;'>

Regeneron has an analyst consensus of Moderate Buy, with a price target consensus of $829.77, which is a 36.6% upside from current levels. In a report issued on May 18, Barclays also maintained a Buy rating on the stock with a $917.00 price target.

Read More on IDYA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).